<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bamias, A.</style></author><author><style face="normal" font="default" size="100%">Papadimitriou, C.</style></author><author><style face="normal" font="default" size="100%">Efstathiou, E.</style></author><author><style face="normal" font="default" size="100%">Rodolakis, A.</style></author><author><style face="normal" font="default" size="100%">Vlahos, G.</style></author><author><style face="normal" font="default" size="100%">Voulgaris, Z.</style></author><author><style face="normal" font="default" size="100%">Bozas, G.</style></author><author><style face="normal" font="default" size="100%">Fountzilas, G.</style></author><author><style face="normal" font="default" size="100%">Aravantinos, G.</style></author><author><style face="normal" font="default" size="100%">Razis, E.</style></author><author><style face="normal" font="default" size="100%">Gika, D.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: A six-year experience of the Hellenic Cooperative Oncology Group</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Cancer</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33749634598&amp;doi=10.1186%2f1471-2407-6-228&amp;partnerID=40&amp;md5=2f9c887eb4644eeff26093a3a2a077ae</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">6</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Background: Surgery can cure a significant percentage of ovarian carcinoma confined to the pelvis. Nevertheless, there is still a 10-50% recurrence rate. We administered paclitaxel/carboplatin as adjuvant treatment in early-stage ovarian carcinoma. Methods: Patients with stages Ia or Ib, Grade 2 or 3 and Ic to IIb (any grade) were included. Patients were treated with 4 cycles of Paclitaxel 175 mg/m2 and Carboplatin [area under the curve (AUC) 6 (Calvert Formula)] every 3 weeks. Results: Sixty-nine patients with no residual disease following cytoreductive surgery and minimal or modified surgical staging were included in this analysis. Grade 3 or 4 neutropenia occured in 29.9% of patients, while neutropenic fever was reported in 4.5%. Neurotoxicity (all Grade 1 or 2) was reported in 50% of cases. Median follow-up was 62 months. 5-year overall survival (OS) and relapse-free survival (RFS) were: 87% (95% confidence intervals [CI]: 78-96) and 79% (95% CI: 69-89), respectively. Significantly fewer patients with stages Ic-IIb and tumor grade 2 or 3 achieved a 5-year RFS than patients with only one of these two factors (73% vs 92%, p = 0.03). Conclusion: Paclitaxel/Carboplatin chemotherapy is a safe and effective adjuvant treatment in early-stage ovarian carcinoma Patients with stages Ic-IIb and tumor grade 2 or 3 may benefit from more extensive treatment. © 2006 Bamias et al; licensee BioMed Central Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :7Export Date: 21 February 2017</style></notes></record></records></xml>